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Case Report 
Improvement of native pulmonary alveolar proteinosis after contralateral single 
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Abstract 
Pulmonary alveolar proteinosis (PAP) is a rare disease characterized by the 
accumulation of surfactant materials in the alveolar spaces due to the imbalance 
of surfactant homeostasis (production and clearance). We herein report a case 
of an eight-year-old girl who developed PAP after bone marrow transplantation 
(BMT) from her mother for the treatment of Diamond-Blackfan-Anemia (DBA). 
The anemia was improved by BMT; however, respiratory dysfunction due to graft-
versus-host disease gradually progressed. She eventually underwent right single 
living-donor lobar lung transplantation (LDLLT) from her mother when she was 
14 years old. A pathological examination of the excised lung confirmed the finding 
of diffuse bronchiolitis obliterans and unexpectedly revealed widespread alveolar 
proteinosis. Interestingly, the ground glass opacification (GGO) of her native left 
lung on chest X-ray was improved after LDLLT. We present the very unique 
clinical course of this patient and discuss the mechanisms underlying the 




Pulmonary alveolar proteinosis (PAP) is a rare disease characterized by the 
accumulation of surfactant materials in the alveolar spaces. Regarding the 
pathophysiology, alveolar macrophages (AMs) lose the ability to remove 
excessive sediments from the alveolar spaces. PAP is commonly classified into 
autoimmune (aPAP), secondary (sPAP), hereditary (hPAP), congenital (cPAP) 
and unclassified PAP (uPAP). aPAP accounts for 90% of cases and is associated 
with the existence of anti-GM-CSF (granulocyte-macrophage colony stimulating 
factor) auto-antibody and an increased number of alveolar foamy macrophages. 
GM-CSF is a monomeric glycoprotein, an activator of STAT5 phosphorylation, 
and an inducer of macrophage maturation. sPAP, accounting for 10% of cases, 
is accompanied by small and immature macrophages and mainly caused by 
hematological diseases, such as myelodysplastic syndrome [1-4]. 
We herein report a case of sPAP that developed in an eight-year-old girl after 
allogeneic bone marrow transplantation (BMT) from her mother for the treatment 
of Diamond-Blackfan-Anemia (DBA), a disease of congenital erythroblast 
deficiency. Although her anemia and hemosiderosis were improved by BMT, 
respiratory dysfunction due to graft-versus-host disease (GVHD) gradually 
progressed. She eventually received right single lung lobar lung transplantation 
(LDLLT) from her mother when she was 14 years old. Unexpectedly, a 
pathological examination revealed widespread sPAP coexisting with diffuse 
bronchiolitis obliterans (BO), a typical pathological form of GVHD. Interestingly, 
the ground glass opacification (GGO) of her native left lung on chest X-ray 
consistent with PAP was improved after LDLLT. The levels of KL-6, which reflects 
the severity of PAP, were also decreased dramatically. We describe the clinical 
course and discuss the pathophysiological mechanisms underlying the 
development and remission of PAP in this case. 
  
Case Presentation 
A four-month-old girl was admitted to our hospital for the treatment of advanced 
anemia. As she met the diagnostic criteria of <1 year old, macrocytic anemia with 
no other significant cytopenia and normal marrow cellularity with a paucity of 
erythroid precursors, the anemia was diagnosed as DBA, a congenital 
erythroblast deficiency. Her familial history did not suggest any congenital 
diseases, including hematological disorders. Her anemia was steroid-resistant 
and rapidly progressive, so she was treated with frequent red blood cell 
transfusion. As a result, she developed hemosiderosis in her organs. Therefore, 
the patient received BMT at eight years old from her mother, whose HLA showed 
five matched haplotypes and one mismatched haplotype from the recipient.  
After BMT, her anemia and hemosiderosis were improved. However, three 
months after the BMT, she showed symptoms of cough and dyspnea, and steroid 
pulse therapy and augmentation of immunosuppressive therapy were 
administered under the diagnosis of progressive GVHD. Cyclosporine and 
tacrolimus could not be used because of the occurrence of convulsion induced 
by reversible posterior leukoencephalopathy (RPLS) [5]. She was finally treated 
with prednisolone (10 mg) and mycophenolate mofetil (MMF [1500 mg]). Despite 
these therapies, the severity of her dyspnea gradually progressed, and home 
oxygen therapy (HOT) was ultimately needed at 10 years old. Her pulmonary 
function tests (PFTs) immediately before lung transplantation showed severe 
mixed restrictive and obstructive impairments (Table 1). She was registered to 
the lung transplant waiting list at 12 years old. At that time, her height and weight 
were 120 cm and 23.3 kg, respectively.  
Chest computed tomography (CT) showed diffuse cystic dilation of peripheral 
bronchi and widespread patchy GGO in the bilateral lung fields. While on the 
waiting list, her respiratory dysfunction rapidly worsened, and she eventually 
underwent right single LDLLT from her mother at 14 years old. The mother's right 
lower lobe was transplanted into the patient’s right thoracic cavity.  
The pathological analysis of the excised right lung showed epithelial injury and 
obstruction of bronchioles with subepithelial fibrotic lesions, which was consistent 
with BO (Figure 1A, B). Diffuse BO was observed in the excised right lung. In 
addition, the retention of eosinophilic materials was observed in most alveolar 
spaces in all fields of the excised right lung. The alveolar eosinophilic material 
was positive for surfactant protein A (SP-A) and periodic acid Schiff (PAS) 
staining, so the diagnosis of PAP was established (Figure 1C, D). She was 
negative for serum GM-CSF antibody.  
She was discharged from the intensive-care unit and the hospital on days 49 and 
65, respectively. She was treated with an unusual post-lung transplant 
immunosuppressive regimen of only 2 mg of prednisolone and 250 mg of MMF 
because the BMT and lung transplant donors were the same person, and the 
HLA of her bone marrow and the right transplanted lower lobe was identical. The 
courses of her postoperative imaging findings and laboratory data are shown in 
Figure 2. Interestingly, the GGOs that were observed in all CT sections of the left 
native lung gradually improved and eventually almost completely disappeared 
(Figure 2A). The value of KL-6, a marker reflecting the severity of the PAP [2], 
normalized (Figure 2B). Her hypoxia and the combined impairments with 
restrictive and obstructive disturbances in the PFTs were also slightly improved 
after lung transplantation (Figure 2B and Table 1). She remains alive and works 
successfully seven years after LDLLT. 
  
Discussion 
The important problem in the present case is whether we could diagnose sPAP 
before lung transplantation. Generally, typical PAP is associated with restrictive 
impairments, while BO is associated with obstructive impairments in PFTs. 
However, both impairments were mixed in this case. In addition, the radiographic 
findings were atypical of PAP or BO. Surgical lung biopsy before lung 
transplantation was difficult due to the invasiveness of the procedure. Thus, it 
might have been difficult to suspect sPAP before lung transplantation in this case. 
Whether or not the choice of lung transplantation using the one antigen 
mismatched maternal lung could be acceptable for rescuing the patient in the 
present case might be difficult to determine because of the lack of effective 
treatment for the devastating situation. 
Ishii reported that sPAP patients accounted for 10% of the 404 total PAP patients 
(n=40) registered from 1999 to 2009 in the database of Niigata University in 
Japan. Blood diseases are found in 88% of sPAP patients as causal diseases, 
with the remaining 12% related to inflammatory and autoimmune diseases. No 
case associated with BMT has been reported in the database [1]. However, a 
careful search of the literature revealed a few reports of PAP after hematopoietic 
stem cell transplantation (HSCT) and BMT [6-8]. These cases were rapidly 
progressive with a fatal outcome, so some cases were diagnosed by an autopsy. 
The authors of those reports considered that immunosuppression before and 
after HSCT or BMT likely suppressed the function of AMs and played a role in the 
development of PAP. Indeed, a retrospective study demonstrated that the use of 
corticosteroids induced macrophage dysfunction, which caused aPAP [9]. 
In the present case, PAP developed after BMT, and the patient was treated with 
prednisolone and MMF in an attempt to manage her GVHD. After LDLLT, the 
immunosuppression was weakened because the HLA of the bone marrow and 
the lung graft was identical (mother’s marrow and lung). Therefore, the 
development of PAP and its remission may be attributed to the context of changes 
in the strength of immunosuppression, as has been described in previous reports. 
A pathological examination of the excised right lung showed the existence of 
widespread PAP and diffuse BO. These findings suggest that the improvement of 
GGO on CT mainly depended on the improvement of PAP, due to the diminished 
extent of immunosuppressive therapy after lung transplantation.  
Reconstruction of the lymphatic vessels was not performed in the present case; 
thus, the drainage of alveolar sediments from alveolar spaces via lymphatic 
vessels by mechanical ventilation might be not the principal reason of 
improvement of GGO. 
Another potential explanation for the observations made in the present study is 
slightly complicated. Recently, the existence of two types of AMs in the lung has 
been reported. One type is derived from progenitors in the fetal lung, while the 
other is derived from circulating monocytes differentiated from hematopoietic 
stem cells in bone marrow [10, 11]. Some clinicians have observed the 
coexistence and slow replacement of donor AMs with recipient AMs in the lung 
over several years in leukemia patients after BMT [12, 13]. Following BMT, the 
immunocompetent cells derived from the donor bone marrow may attack recipient 
resident AMs, thereby inducing the loss of the function of recipient AMs, which 
causes sPAP. The improvement in PAP after LDLLT in the present case may be 
explained by the hypothesis that the donor AMs from the right transplanted lung 
may hematogenously or lymphogenously or trans-tracheal infiltrate the left native 
lung, thereby weakening the attack of donor immunocompetent cells against 
recipient AMs or inducing chimerism of AMs with dominant donor cells. However, 
no conclusive studies or case reports support this hypothesis.  
Despite difficulty in clearly defining the underlying mechanisms, the present case 
report describes the unique clinical course of a patient with PAP who underwent 
BMT followed by LDLLT.  
Figure legends 
Figure 1. Pathology of the excised left lung. Epithelial injury and obstruction of 
bronchioles with subepithelial fibrotic lesions, which was consistent with 
bronchioliits obliterans (A: hematoxylin-eosin at 100x magnification, B:  Elastica-
Masson at 100x magnification). Massive eosinophilic material deposition in the 
alveolar space (C, hematoxylin-eosin at 100x magnification). The material in the 
alveolar space was positive on periodic acid-Schiff (PAS) stain (D). 
 
Figure 2. The courses of her postoperative imaging findings and laboratory data. 
The ground glass opacification of the left native lung on chest X-ray and CT, which 
is consistent with pulmonary alveolar proteinosis, improved and eventually 
disappeared after right single lung lobar lung transplantation (LDLLT) (A). The 
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Table 1. Pulmonary function test 
  
Right before lung 
transplantation 
Half year after 
transplantation 
Six Year after lung 
transplantation 
VC (L) 0.59 0.85 0.84 
%VC 43.4 61.6 35.6 
FVC (L) 0.52 0.86 0.83 
%FVC 36.9 59.7 35.2 
FEV1.0 (L) 0.3 0.62 0.55 
FEV1.0/FVC (%) 57.69 72.09 66.27 
PEF (L) 0.72 1.53 1.2 
V75 (L/S) 0.52 1.3 1.03 
V50 (L/S) 0.14 0.52 0.33 
V25 (L/S) 0.08 0.19 0.13 
MMF (L/S) 0.14 0.36 0.27 
FRC (L)     1.1 
RV (L)     0.91 
TLC (L)     1.75 
RV/TLC (%)     52 
BW (kg) 23.3 20 25 
Height (cm) 120 121 120 
Body surface area (m2) 0.881 0.83 0.908 
 


